Abstract
Diffuse malignant mesothelioma is a tumor arising from the serosal surfaces of the pleura, peritoneum, pericardium, or tunica vaginalis testis. Although the tumor is exceedingly uncommon, there is a substantial interest in this disease, as either biological or occupational and medical-legal issues are concerned: asbestos is the principal carcinogen associated with malignant mesothelioma, and up to 8 million living persons in the USA have been occupationally exposed to asbestos over the last five decades (Robinson and Lake 2005).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Altieri DC (2003a) Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3:46–54
Altieri DC (2003b) Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 22:8581–8589
Antman KH, Blum RH, Greenberger JS et al. (1980) Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med 68:356–362
Antman KH, Corson JM, Li FP et al. (1983) Malignant mesothelioma following radiation exposure. J Clin Oncol 1:695–700
Arancia G, Crateri Trovalusci P, Mariutti G et al. (1989) Ultrastructural changes induced by hyperthermia in Chinese hamster V79 fibroblasts. Int J Hyperthermia 5:341–350
Archer VE, Rom WN (1983)Trends in mortality of diffuse malignant mesothelioma of pleura. Lancet 2:112–113
Baratti D et al. (2007) Circulating CA125 in patients with peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol 14:500–508
Baris YI, Sahin AA, Ozesmi M et al. (1978) An outbreak of pleural mesothelioma and chronic fibrosing pleurisy in the village of Karain/Urgup in Anatolia. Thorax 33:181–192
Barlogie B, Corry PM, Drewinko B (1980) In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum(II) and mitomycin C. Cancer Res 40:1165–1168
Berghmans T et al. (2002) Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with metaanalysis. Lung Cancer 38:112–121
Blackburn EH (2001) Structure and function of telomeres. Nature 350:569–573
Brigand C, Monneuse O, Mohamed F et al. (2006) Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study. Ann Surg Oncol 13:405–412
Bryan TM, Englezou A, Dalla-Pozza L et al. (1997) Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med 3:1271–1274
Cain J, Nori D, Huvos A et al. (1983) The role of radioactive colloids in malignant peritoneal mesotheliomas. Gynecol Oncol 16:263–274
Calderwood SK, Hahn GM (1983) Thermal sensitivity and resistance of insulin-receptor binding. Biochim Biophys Acta 756:1–8
Carmignani CP, Sugarbaker TA, Bromley CM et al. (2003) Intraperitoneal cancer dissemination: mechanisms of the patterns of spread. Cancer Metastasis Rev 22:465–472
Chan PS, Balfour TW, Bourke JB et al. (1975) Peritoneal nesothelioma. Br J Surg 62:576–580
Churg A, Cagle PT, Roggli VL (2006) Tumors of the serosal membranes. In: Atlas of tumor pathology, IV series. AFIP, Washington DC
Cong YS et al. (2002) Human telomerase and its regulation. Microbiol Mol Biol Rev 66:407–425
Dedrick RL, Flessner MF (1997) Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J Natl Cancer Inst 89:480–487
Deraco M, Santoro N, Carraro O et al. (1999) Peritoneal carcinomatosis: feature of dissemination. A review. Tumori 85:1–5
Deraco M, Rossi CR, Pennacchioli E et al. (2001) Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a phase II clinical study. Tumori 87:120–126
Deraco M, Raspagliesi F, Kusamura S et al. (2003a) Management of peritoneal surface component of ovarian cancer. Surg Oncol Clin N Am 12:561–583
Deraco M, Casali P, Inglese MG et al. (2003b) Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion. J Surg Oncol 83:147–153
Deraco M, Baratti D, Inglese MG et al. (2004) Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP): a strategy that has confirmed its efficacy in patients with pseudomyxoma peritonei. Ann Surg Oncol 11:393–398
DuBose DA, Hinkle JR, Morehouse DH et al. (1998) Model for environmental heat damage of the blood vessel barrier. Wilderness Environ Med 9:130–136
Dunham MA, Neumann AA, Fasching CL et al. (2000) Telomere maintenance by recombination in human cells. Nat Genet 26:447–450
Eggermont AM et al. (1987) Laparotomy enhances intraperitoneal tumor growth and abrogates the antitumor effects of interleukin-2 and lymphokine-activated killer cells. Surgery 102:71–78
Eisenkop SM, Friedman RL, Wang HJ (1998) Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol 69:103–108
Elias D, Blot F, El Otmany A et al. (2001) Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer 92:71–76
Eltabbakh GH, Piver MS, Hempling RE et al. (1999) Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol 70:6–12
Engelhardt R (1987) Hyperthermia and drugs. Rec Res Cancer Res 104:136–203
Feldman AL, Libutti SK, Pingpank JF et al. (2003) Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 21:4560–4567
Fujimoto S, Takahashi M, Mutou T et al. (1997) Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery. Cancer 79:884–891
Gazdar AF, Carbone M (2003) Molecular pathogenesis of mesothelioma and its relationship to Simian virus 40. Clin Lung Cancer 5:177–181
Gilly FN, Carry PY Sayag AC et al. (1994) Regional chemotherapy (with mitomycin C) and intra-operative hyperthermia for digestive cancers with peritoneal carcinomatosis. Hepatogastroenterology 41:124–129
Glehen O, Mithieux F, Osinsky D et al. (2003) Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study. J Clin Oncol 21:799–806
Gordon GJ, Appasani K, Parcells JP et al. (2002) Inhibition of apoptosis protein-1 promotes tumor cell survival in mesothelioma. Carcinogenesis 23:1017–1024
Hahn WC, Counter CM, Lundberg AS et al. (1999) Creation of human tumour cells with defined genetic elements. Nature 400:464–468
Harmon RL, Sugarbaker PH (2005) Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int Semin Surg Oncol 2:3–13
Hassan R, Alexander R (2005) Nonpleural mesotheliomas: mesothelioma of the peritoneum, tunica vaginalis ad pericardium. Hemat Oncol Clin N Am 19:1067–1087
Hassan R, Alexander R, Antman K et al. (2006) Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference. Ann Oncol (in press)
Henson JD, Neumann AA, Yeager TR et al. (2002) Alternative lengthening of telomeres in mammalian cells. Oncogene 21:598–610
Henson JD, Hannay JA, McCarthy SW et al. (2005) A robust assay for alternative lengthening of telomeres in tumours shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin Cancer Res 11:217–225
Hettinga JV, Lemstra W, Meijer C et al. (1997) Mechanism of hyperthermic potentiation of cisplatin action in cisplatin-sensitive and-resistant tumor cells. Br J Cancer 75:1735–1743
Iwamoto A (1989) [Intraoperative chemotherapy with intraperitoneal activated carbon particles adsorbing mitomycin C against peritoneal dissemination of gastric cancer]. Gan To Kagaku Ryoho 16:2748–2751
Janne PA, Wozniak AJ, Belani CP et al. (2006) Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer 7:40–46
Jacquet P, Sugarbaker PH (1996)Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 15:49–58
Kannerstein M, Churg J (1977) Peritoneal mesothelioma. Hum Pathol 8:83–94
Krug LM (2005) An overview of chemotherapy for mesothelioma. Hemat Oncol Clin N Am 19:117–136
Kumaki F, Kawai T, Churg A et al. (2002) Expression of telomerase reverse transcriptase in malignant mesotheliomas. Am J Surg Pathol 26:365–370
Kusamura S, Younan R, Baratti D et al. (2006) Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of peritoneal surface malignancies: analysis of morbidity and mortality in 209 cases treated with closed abdomen technique. Cancer 106:1144–1153
Kuzuya T, Yamauchi M, Ito A et al. (1994) Pharmacokinetic characteristics of 5-fluorouracil and mitomycin C in intraperitoneal chemotherapy. J Pharm Pharmacol 46:685–689
Langer JC et al. (1993) Intraperitoneal cisplatin and etoposide in peritoneal mesothelioma: favorable outcome with multimodality approach. Cancer Chemother Pharmacol 32:204–208
Lederman GS, Recht A, Herman T et al. (1987) Longterm survival in peritoneal mesothelioma: the role of radiotherapy and combined modality treatment. Cancer 59:1882–1886
Leigh J, Robinson BWS (2002) The history of mesothelioma in Australia. In: Robinson BWS, Chahinian PA (eds) Mesothelioma. Martin Dunitz, London, pp 55–210
Leunig M, Goetz AE, Dellian M et al. (1992) Interstitial fluid pressure in solid tumors following hyperthermia: possible correlation with therapeutic response. Cancer Res 52:487–490
Loggie BW, Fleming RA, Mc Quellon RP et al. (2001) Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg 67:999–1003
Markman M, Kelsen D (1992) Efficacy of cisplatin-based intra-peritoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol 118:547–550
Maurer F, Egloff B (1975) Malignant peritoneal mesothelioma after cholangiography with thorotrast. Cancer 36:1381–1385
McDonald JC (1985) Health implications of environmental exposure to asbestos. Environ Health Perspect 62:318–329
McDonald JC (2000) Asbestos. In: McDonald JC (ed) Epidemiology of work related disease. BMJ Books, London, pp 85–108
Moertel CG (1972) Peritoneal mesothelioma. Gastroenterology 63:346–350
Murajama T (2004) Emerging health effects of asbestos in Asia. In: Proceedings of the global asbestos congress, Tokyo, November 19–21, 2004: 17, abstract
Nonaka D, Kusamura S, Baratti D et al. (2005) Diffuse malignant mesothelioma of the peritoneum. Cancer 104:2181–2188
Oken MM, Creech RH, Tormey DC et al. (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655
Ordonez NG (1998) Value of cytokeratin 5/6 immunostaining in distinguish epithelial mesothelioma of the pleura from lung adenocarcinoma. Am J Surg Pathol 22:1215–1221
Ozols RF, Young RC (1987) Ovarian cancer. Curr Probl Cancer 11:57–122
Park BJ, Alexander HR, Libutti SK et al. (1999) Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion(CHPP). Ann Surg Oncol 6:582–590
Pass HI, Lott D, Lonardo F et al. (2005) Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 353:1564–1573
Peto J, Hodgson JT, Matthews FE et al. (1995) Continuing increase in mesothelioma mortality in Britain. Lancet 345:535–539
Peto J, Decarli A, La Vecchia C et al. (1999) The European mesothelioma epidemic. Br J Cancer 79:666–672
Pisick E, Salgia R (2005) Molecular biology of malignant mesothelioma: a review. Hemat Oncol Clin N Am 19
Price B (1997) Analysis of current trends in the United States mesothelioma incidence. Am J Epidemiol 45:211–218
Robinson BWS, Creaney J, Lake R et al. (2003) Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 362:1612–1616
Robinson BWS, Lake RA (2005) Advanced in malignant mesothelioma. N Engl J Med 353:1591–603
Robinson BWS, Musk AW, Lake RA et al. (2005) Malignant mesothelioma. Lancet 366:397–408
Roushdy-Hammady I, Siegel J, Emri S et al. (2001) Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet 357:444–445
van Ruth S, Verwaal VJ, Hart AA et al. (2003) Heat penetration in locally applied hyperthermia in the abdomen during intra-operative hyperthermic intraperitoneal chemotherapy. Anticancer Res 23:1501–1508
Sadeghi B, Arvieux C, Glehen O et al. (2000) Peritoneal carcinomatosis from non-gynaecologic malignancies. Results of the EVOCAPE1 multicentric prospective study. Cancer 88:358–363
Sebbag G, Yan H, Shmookler BM et al. (2000) Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg 87:1587–1593
Shen P, Levine EA, Hall J et al. (2003) Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Arch Surg 138:26–33
Spirtas R, Heineman EF, Bernstein L et al. (1994) Malignant mesothelioma: attributable risk of asbestos exposure. Occup Environ Med 51:804–811
Stewart JH, Shen P, Levine EA (2005) Intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: current status and future directions. Ann Surg Oncol 12:765–777
Sugarbaker PH (1994) Pseudomyxoma peritonei: a cancer whose biology is characterized by a redistribution phenomenon. Ann Surg 219:109–111
Sugarbaker PH (1999a) Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 6:727–731
Sugarbaker PH (1999b) Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol 43[Suppl]:S15–S25
Sugarbaker PH (2003) Peritonectomy procedures. Surg Oncol Clin North Am 12:703–727
Sugarbaker PH, Graves T, DeBruijn EA et al. (1990) Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacological studies. Cancer Res 50:5790–5794
Sugarbaker PH, Welch LS, Mohamed F et al. (2003) A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin North Am 12:605–621
Sugarbaker PH et al. (2006) Comprehensive management of diffuse malignant peritoneal mesothelioma. EJSO (in press)
Takayhashi H (2004) Emerging health effects of asbestos in Asia. In: Proceedings of the global asbestos congress, Tokyo, November 19–21, 2004: 2, abstract
Tentes AAK, Trispsiannis G, Markakidis SK et al. (2003) Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer. Eur J Surg Oncol 29:69–73
Vaupel PW (1997) The influence of tumor blood flow and micro-environmental factors on the efficacy of radiation, drugs and localized hyperthermia. Klin Paediatr 209:243–249
Vlasveld LT, Gallee MP, Rodenhuis S et al. (1991) Intraperitoneal chemotherapy for malignant peritoneal mesothelioma. Eur J Cancer 27:732–734
Vogelzang NJ, Rusthoven JJ, Symanowski J et al. (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636–2644
Wagner JC, Sleggs CA, Marchand P (1960) Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 17:260–271
Whitaker D (2000) The cytology of malignant mesothelioma. Cytopathology 11:139
Witkamp AJ, de Bree E, Kaag MM et al. (2001) Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. Eur J Cancer 37:979–984
Xia C, Xu Z, Yuan X et al. (2002) Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides. Mol Cancer Ther 1:687–694
Xu M, Myerson RJ, Straube WL et al. (2002) Radiosensitization of heat resistant human tumour cells by 1 hour at 41.1 degrees C and its effect on DNA repair. Int J Hyperthermia 18:385–403
Yan TD, Haveric N, Carmignani CP et al. (2005a) Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Cancer 103:839–849
Yan TD, Haveric N, Carmignani CP et al. (2005b) Computed tomographic characterization of malignant peritoneal mesothelioma. Tumori 91:394–400
Younan R, Kusamura S, Baratti D et al. (2005) Bowel complications in 203 cases of peritoneal surface malignancies treated with peritonectomy and closed-technique intraperitoneal hyperthermic perfusion. Ann Surg Oncol 12:910–918
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Deraco, M., Baratti, D., Zaffaroni, N., Cabras, A.D., Kusamura, S. (2007). Advances in Clinical Research and Management of Diffuse Peritoneal Mesothelioma. In: González-Moreno, S. (eds) Advances in Peritoneal Surface Oncology. Resent Results in Cancer Research, vol 169. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-30760-0_13
Download citation
DOI: https://doi.org/10.1007/978-3-540-30760-0_13
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-30759-4
Online ISBN: 978-3-540-30760-0
eBook Packages: MedicineMedicine (R0)